Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767775 | 0.92 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL205216 | 0.88 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL3097843 | 0.87 | SMN1; SMN2 (0.97) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5360566 | 0.87 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5360568 | 0.87 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL14502183 | 0.87 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL485156 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL5752708 | 0.86 | SMN1; SMN2 (0.75) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL2712105 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL188053 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| CN-118147098-B | Leucine dehydrogenase mutant and application thereof in chiral nitrogen heterocyclic amine synthesis | 江南大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025050016-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025049964-A1 | BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250059198-A1 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-119317623-A | Tricyclic quinolone BCL6 bifunctional degradation agents | 树线生物科学公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4436966-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | MERCK SHARP & DOHME LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002068409-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-0863757-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| EP-0863757-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5792778-A | TREATMENT OF CYTOKINE MEDIATED DISEASES | MERCK & CO., INC. (US) | 1998-08-11 | — | — | US | disclosed |
| EP-0625509-B1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LTD (GB) | 1997-07-30 | — | — | EP | disclosed |
| WO-1997005877-A1 | 2-SUBSTITUTED ARYL PYRROLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 1997-02-20 | — | — | WO | disclosed |
| US-5521199-A | TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0625509-A1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885 |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 4391/4885NPC1 1612/4885RAB9A 3106/4885 |
| US-20250059198-A1 | BRM DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, RBX1, BRAP | SMN1; SMN2 663/4885NPC1 2700/4885RAB9A 1951/4885 |
| US-20020165241-A1 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists | GRIN1, GRIN2B, GRIN2A | SMN1; SMN2 505/4885NPC1 1808/4885RAB9A 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.